Overview

• The team adapted a human MSC differentiation protocol to canine iPSCs, leading to published findings in Regenerative Therapy on May 29, 2025.
• Urine-derived somatic cells emerged as the most effective source for generating robust iPSCs that differentiate into high-quality MSCs.
• iPSC-derived MSCs demonstrated superior proliferation rates and immunomodulatory capabilities compared with traditional tissue-harvested MSCs.
• This approach overcomes donor variability and senescence limitations inherent to MSCs sourced directly from adipose tissue or bone marrow.
• Upcoming canine trials will explore application of these cells in osteoarthritis and other inflammatory disorders.